Lexaria Bioscience Corp.
LEXX · NASDAQ
8/31/2025 | 8/31/2024 | 8/31/2023 | 8/31/2022 | |
|---|---|---|---|---|
| Market Cap | – | $48,421 | $6,945 | $17,420 |
| - Cash | $1,802 | $6,500 | $1,352 | $5,813 |
| + Debt | $79 | $137 | $164 | $50 |
| Enterprise Value | – | $42,059 | $5,757 | $11,657 |
| Revenue | $706 | $464 | $226 | $255 |
| % Growth | 52% | 105.2% | -11.4% | – |
| Gross Profit | $703 | $459 | $195 | $184 |
| % Margin | 99.6% | 99% | 86.1% | 71.9% |
| EBITDA | -$11,881 | -$5,677 | -$6,389 | -$6,516 |
| % Margin | -1,683% | -1,222.8% | -2,824.2% | -2,551.4% |
| Net Income | -$11,902 | -$5,795 | -$6,665 | -$7,269 |
| % Margin | -1,686% | -1,248.2% | -2,946.4% | -2,846.3% |
| EPS Diluted | -0.66 | -0.47 | -1.01 | -1.24 |
| % Growth | -40.4% | 53.5% | 18.5% | – |
| Operating Cash Flow | -$10,450 | -$4,959 | -$5,881 | -$4,879 |
| Capital Expenditures | $0 | -$43 | -$170 | -$131 |
| Free Cash Flow | -$10,450 | -$5,002 | -$6,051 | -$5,011 |